Niridazole

Niridazole

SCHEMBL126396

O=C1NCCN1c1ncc([N+](=O)[O-])s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
TSHR P16473 1/20 1.00
HSD17B10 Q99714 1/20 1.00
ALDH1A1 P00352 5/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
MPI P34949 1/20 0.46
MAPK8 P45983 2/20 0.38
MAPK9 P45984 2/20 0.38
MAPK10 P53779 2/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
MAPT P10636 4/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
HTT P42858 3/20 0.38
S1PR4 O95977 2/20 0.38
S1PR1 P21453 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11884135 0.90 SMN1; SMN2 (0.81) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11737155 0.80 CYP1A2 (0.65) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11735227 0.78 SMN1; SMN2 (0.62) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11736694 0.78 SMN1; SMN2 (0.62) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL2826648 0.78 SMN1; SMN2 (0.64) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11733666 0.77 SMN1; SMN2 (0.61) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11732378 0.77 SMN1; SMN2 (0.61) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11738041 0.76 SMN1; SMN2 (0.61) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
SCHEMBL11743012 0.76 SMN1; SMN2 (0.59) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10
Niridazole SCHEMBL27347458 0.75 SMN1; SMN2 (0.59) SMN1; SMN2CYP1A2CYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4586826-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL In the Bowl Animal Health, Inc. (US) 2025-07-23 EP claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
CN-114071074-B Picture acquisition, processing and display method and system for Beidou No. three short message channel 武汉兴图新科电子股份有限公司 2024-12-24 CN claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
WO-2024059837-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL IN THE BOWL ANIMAL HEALTH, INC. (US) 2024-03-21 WO claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
CN-114071074-A Method and system for acquiring, processing and displaying picture of Beidou No. three short message channel 武汉兴图新科电子股份有限公司 2022-02-18 CN claimed
US-20200246573-A1 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS STREETERVILLE CAPITAL, LLC 2020-08-06 US claimed
US-20190142817-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES THE TEXAS A&M UNIVERSITY SYSTEM 2019-05-16 US claimed
EP-3078664-B1 ANTIPARASITIC DIHYDROAZOLE COMPOSITIONS MERIAL INC (US) 2019-02-20 EP claimed
US-20050246023-A1 Disc shunt for treating back pain YEUNG JEFFREY E 2005-11-03 US claimed
EP-0507629-B1 Sustained release capsule and formulations for insertion into rumen LILLY CO ELI (US) 1997-01-22 EP claimed
US-5567434-A DISSOLVING COMPOUND AND LIPID IN APROTIC SOVENT, EXTRUDING INTO AQUEOUS SOLUTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-10-22 US claimed
EP-0467954-B1 PREPARATION OF LIPOSOME AND LIPID COMPLEX COMPOSITIONS UNIV CALIFORNIA (US) 1996-05-01 EP claimed
US-5277914-A Encapsulation in non-halogenated aprotic solvent THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-01-11 US claimed
US-5277912-A Sustained release capsule and formulations ELI LILLY AND COMPANY (US) 1994-01-11 US claimed
US-5232441-A Method of treating schistosomal infestations by iontophoresis PHYSION S.R.L. (IT) 1993-08-03 US claimed
EP-0507629-A1 Sustained release capsule and formulations for insertion into rumen ELI LILLY AND COMPANY (US) 1992-10-07 EP claimed
US-5077057-A Dissolving in aprotic solvent; extrusion into aqueous solution THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1991-12-31 US claimed
EP-0305968-A2 Compositions against protozoal diseases YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) 1989-03-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142817-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES ABCC1, SLC11A2, ABCB11 SMN1; SMN2 4266/4885CYP1A2 441/4885CYP3A4 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.